The drug maker Pfizer said on Wednesday that its coronavirus vaccine was 95 percent effective and had no serious side effects — the first set of complete results from a late-stage vaccine trial as Covid-19 cases skyrocket around the globe.
The data showed that the vaccine prevented mild and severe forms of Covid-19, the company said. And it was 94 percent effective in older adults, who are more vulnerable to developing severe Covid-19 and who do not respond strongly to some types of vaccines.
Pfizer, which developed the vaccine with its partner BioNTech, said the companies planned to apply to the Food and Drug Administration for emergency authorization “within days,” raising hopes that a working vaccine could soon become a reality.
If the F.D.A. authorizes the two-dose vaccine, Pfizer has said that it could have up to 50 million doses available by the end of the year, and up to 1.3 billion by the end of next year.
However, only about half of its supply
will go to the United States this year, or enough for about 12.5 million
people — a sliver of the American population of 330 million. Americans
will receive the vaccine for free, under a $1.95 billion deal the
federal government reached with Pfizer for 100 million doses.
No comments:
Post a Comment
ANONYMOUS COMMENTS WILL NOT BE POSTED!
please use either your real name or a pseudonym.